Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 80.6% in June

Biorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totaling 1,281,247 shares, a decrease of 80.6% from the May 31st total of 6,588,718 shares. Approximately 5.8% of the shares of the stock are sold short. Based on an average daily volume of 1,895,030 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biorestorative Therapies currently has a consensus rating of “Sell”.

Get Biorestorative Therapies alerts:

Get Our Latest Stock Report on BRTX

Biorestorative Therapies Stock Down 0.8%

Biorestorative Therapies stock opened at $0.39 on Friday. Biorestorative Therapies has a 12-month low of $0.16 and a 12-month high of $1.89. The firm’s fifty day moving average is $0.30 and its 200 day moving average is $0.56. The company has a market capitalization of $10.04 million, a PE ratio of -0.37 and a beta of 0.67.

Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.31 million. Sell-side analysts expect that Biorestorative Therapies will post -0.66 EPS for the current fiscal year.

Institutional Trading of Biorestorative Therapies

Several hedge funds have recently added to or reduced their stakes in BRTX. Virtu Financial LLC increased its stake in shares of Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares during the period. DRW Securities LLC purchased a new stake in Biorestorative Therapies in the fourth quarter worth about $55,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Biorestorative Therapies in the 3rd quarter worth approximately $152,000. 69.38% of the stock is owned by institutional investors.

About Biorestorative Therapies

(Get Free Report)

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.

Read More

• Five stocks we like better than Biorestorative Therapies
• MDA Space Targets US Defense Market With $620M Acquisition
• Carnival’s Second Quarter: Is the Stock Still Complicated?
• Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
• Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal

Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.